3. Systemic MMF versus systemic CsA in people undergoing high‐risk keratoplasty.

Outcome	Systemic MMF	Systemic CsA	RR (95% CI)
Clear graft survival at 3 years	25/27 (92.6%)	21/25 (84.0%)	1.10 (0.90 to 1.35)
Graft rejection (immune reactions) at 3 years	8/27 (29.6%)	5/25 (20.0%)	1.48 (0.56 to 3.93)

Data from Reinhard 2001

MMF: mycophenolate mofetil
 CsA: cyclosporine A
 RR: risk ratio
 CI: confidence interval